Response to Pazopanib in Patients with Relapsed Osteosarcoma

Kunal R. Elete, Karen H. Albritton, Lauren J. Akers, Riyaz Mahammad Basha, Anish Ray

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence prognosis adversely in osteosarcoma. Relapse of osteosarcoma, typically occurring within the first 18 months of therapy, with an incidence rate of 50% is treated with surgery, chemotherapy, and targeted therapy. Here, we discuss 2 patients treated with pazopanib, a multi-tyrosine kinase inhibitor presently approved to treat renal cell carcinoma and soft tissue sarcomas. Case 1 achieved positive response and remains on pazopanib. Case 2 sustained gastrointestinal toxicity requiring suspension of drug, despite achieving stable disease.

Original languageEnglish
JournalJournal of Pediatric Hematology/Oncology
DOIs
StateAccepted/In press - 1 Jan 2018

Fingerprint

Osteosarcoma
Renal Cell Carcinoma
Skeleton
Sarcoma
Protein-Tyrosine Kinases
Neoplasms
Suspensions
Necrosis
Recurrence
Drug Therapy
Incidence
Therapeutics
Pharmaceutical Preparations
pazopanib

Keywords

  • MAP
  • oncology
  • pazopanib
  • pediatric osteosarcoma
  • relapsed

Cite this

Elete, Kunal R. ; Albritton, Karen H. ; Akers, Lauren J. ; Basha, Riyaz Mahammad ; Ray, Anish. / Response to Pazopanib in Patients with Relapsed Osteosarcoma. In: Journal of Pediatric Hematology/Oncology. 2018.
@article{446f8962bfe04570abfc23fe5904e3bd,
title = "Response to Pazopanib in Patients with Relapsed Osteosarcoma",
abstract = "Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90{\%} tumor necrosis have all been known to influence prognosis adversely in osteosarcoma. Relapse of osteosarcoma, typically occurring within the first 18 months of therapy, with an incidence rate of 50{\%} is treated with surgery, chemotherapy, and targeted therapy. Here, we discuss 2 patients treated with pazopanib, a multi-tyrosine kinase inhibitor presently approved to treat renal cell carcinoma and soft tissue sarcomas. Case 1 achieved positive response and remains on pazopanib. Case 2 sustained gastrointestinal toxicity requiring suspension of drug, despite achieving stable disease.",
keywords = "MAP, oncology, pazopanib, pediatric osteosarcoma, relapsed",
author = "Elete, {Kunal R.} and Albritton, {Karen H.} and Akers, {Lauren J.} and Basha, {Riyaz Mahammad} and Anish Ray",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/MPH.0000000000001375",
language = "English",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins Ltd.",

}

Response to Pazopanib in Patients with Relapsed Osteosarcoma. / Elete, Kunal R.; Albritton, Karen H.; Akers, Lauren J.; Basha, Riyaz Mahammad; Ray, Anish.

In: Journal of Pediatric Hematology/Oncology, 01.01.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Response to Pazopanib in Patients with Relapsed Osteosarcoma

AU - Elete, Kunal R.

AU - Albritton, Karen H.

AU - Akers, Lauren J.

AU - Basha, Riyaz Mahammad

AU - Ray, Anish

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence prognosis adversely in osteosarcoma. Relapse of osteosarcoma, typically occurring within the first 18 months of therapy, with an incidence rate of 50% is treated with surgery, chemotherapy, and targeted therapy. Here, we discuss 2 patients treated with pazopanib, a multi-tyrosine kinase inhibitor presently approved to treat renal cell carcinoma and soft tissue sarcomas. Case 1 achieved positive response and remains on pazopanib. Case 2 sustained gastrointestinal toxicity requiring suspension of drug, despite achieving stable disease.

AB - Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence prognosis adversely in osteosarcoma. Relapse of osteosarcoma, typically occurring within the first 18 months of therapy, with an incidence rate of 50% is treated with surgery, chemotherapy, and targeted therapy. Here, we discuss 2 patients treated with pazopanib, a multi-tyrosine kinase inhibitor presently approved to treat renal cell carcinoma and soft tissue sarcomas. Case 1 achieved positive response and remains on pazopanib. Case 2 sustained gastrointestinal toxicity requiring suspension of drug, despite achieving stable disease.

KW - MAP

KW - oncology

KW - pazopanib

KW - pediatric osteosarcoma

KW - relapsed

UR - http://www.scopus.com/inward/record.url?scp=85058165728&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001375

DO - 10.1097/MPH.0000000000001375

M3 - Article

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

ER -